
via Monash University
A multi-disciplinary project driven by EMBL Australia researchers at Monash University and Harvard University has found a way to make antibiotics more effective against antibiotic-resistant bacteria – also known as ‘superbugs.
Antimicrobial resistance to superbugs has been evolving and is one of the top 10 global public health threats facing humanity, according to the World Health Organization.
This new research will provide a pathway to increasing the effectiveness of antibiotics, without clinicians having to resort to risky strategies of giving patients higher doses or relying on the discovery of new types of antibiotics.
During a bacterial infection, the body uses molecules called chemoattractants to recruit neutrophils to the site of the infection. Neutrophils are immune cells with the ability to encapsulate and kill dangerous bacteria, critical to the immune response. Researchers attached a chemoattractant to an antibiotic, enabling them to enhance the recruitment of immune cells and improve their killing ability.
The findings have now been published in Nature Communications.
“When looking at how our immune system can fight bacteria there are two important aspects we look at. The first is our ability to entrap bacterial cells and kill them. The second is the signals – the chemoattractants – calling for more neutrophils, white blood cells which lead the immune system’s response to resolve infection,” said Dr Jennifer Payne, the lead researcher from EMBL Australia and the Monash Biomedicine Discovery Institute.
The researchers linked a chemoattractant known as formyl peptide to vancomycin, a commonly used antibiotic that binds to the surface of the bacteria, and performed their studies on golden staph infections, one of the more problematic antibiotic-resistant bacteria.
“We’ve been working on using dual-function antibiotic-chemoattractant ‘hybrids’, which improve the recruitment of neutrophils and increase the engulfing and killing of the bacteria,” said Dr Payne.
“By stimulating our powerful immune system in this way with the immunotherapeutic antibiotic, we’ve shown in mouse models that the treatment is 2-fold more effective than just using the antibiotic alone at one-fifth lower dose,” said Associate Professor Max Cryle, an EMBL Australia Group Leader at the Monash Biomedicine Discovery Institute.
“This very promising new avenue of research is bringing a lot of potential benefits to the ever-increasing threat of drug-resistant superbugs,” said Associate Professor Cryle.
Instrumental to the project was funding from VESKI and Melbourne sister city foundation that took Dr Payne across the world to Boston to learn and carry out microfluidic research learning and collaborating with Associate Professor Daniel Irima, and Dr Felix Ellett, Harvard experts in this field.
“Microfluidics was ground-breaking for this research, as it allowed us to generate an infection-on-a-chip to monitor the recruitment of human immune cells, and observe in real-time how our immunotherapeutic enhances their ability to kill MRSA. Just like what would happen in our body” said Dr Payne,
Partners are being sought to continue this research into clinical trials with the potential of developing a preventative antibiotic strategy in the intensive care environment to protect our most vulnerable.
The work has resulted in a patent covering the immunotherapeutic, with the IP owned by Monash University.
Original Article: Researchers discover a way to increase the effectiveness of antibiotics
More from: Monash University | Harvard University
The Latest on: Antibiotic effectiveness
- Some drug stores restricting sales of emergency contraception to cope with increased demandon July 1, 2022 at 10:04 am
Rite Aid is temporarily limiting sales of Plan B and similar pills, in its Northeast Ohio stores and nationally, to three packages per customer ...
- Cancer drug helped delay progression of Duchenne muscular dystrophy in miceon July 1, 2022 at 9:37 am
Researchers at UBC’s School of Biomedical Engineering have discovered that an existing cancer drug could have potential as a treatment for muscular dystrophy.
- WVa opioid trial verdict still pending nearly a year lateron July 1, 2022 at 7:21 am
Now, nearly a year later, there’s still no verdict, and a landmark case remains a book without a final chapter — even as the full dimensions of addiction, desperation, broken families and death ...
- Celldex, continuing comeback, adds to early promise for skin disease drugon July 1, 2022 at 5:51 am
New study results show the treatment appears as effective, or stronger, than standard treatment for chronic urticarias, a common condition that’s proving a tough target for drugmakers.
- Kids under 5 can finally get the Covid-19 vaccine. What should parents consider?on July 1, 2022 at 3:34 am
By Katia Hetter, CNN Parents of children under age 5 can finally get their kids the coronavirus vaccine. The US Food and Drug Administration and US Centers for Disease Control and Prevention have ...
- New Research in Drug Combinations Show Efficacy in Treating Diabetes and Obesityon July 1, 2022 at 1:15 am
Research that has been carried out via a collaboration between Canadian and German researchers has found that new drug combinations may be more effective at treating obesity and diabetes than single ...
- Novavax COVID vaccine surprisingly effective against all Omicron variantson June 29, 2022 at 6:09 pm
Biotech company Novavax has revealed its COVID-19 vaccine can generate effective immune responses against all circulating Omicron variants. The unexpected data was delivered to an advisory panel ...
- Oral Antiviral Drug Effective against Respiratory Syncytial Viruson June 27, 2022 at 10:39 am
ATLANTA, GA — An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding ...
- Experimental Drug May Induce Effective Responses in Patients With Liver Cancer, Early Study Findings Showon June 24, 2022 at 12:00 pm
Treatment with an experimental drug delivered through a minimally invasive procedure ... is thought to dampen the cytotoxic (cell-damaging) effects of doxorubicin.” According to the National Cancer ...
- Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by Biomedical Sciences researcherson June 24, 2022 at 11:00 am
ATLANTA—An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that ...
via Bing News
The Latest on: Antibiotic effectiveness
via Google News
Add Comment